Portola Pharmaceuticals CEO Scott Garland receives $5.8M in 2018

Portola Pharmaceuticals reports 2018 executive compensation

By ExecPay News

Published: April 19, 2019

Portola Pharmaceuticals reported fiscal year 2018 executive compensation information on April 19, 2019.
In 2018, seven executives at Portola Pharmaceuticals received on average a compensation package of $3.7M, a 17% increase compared to previous year.
Average pay of disclosed executives at Portola Pharmaceuticals
Scott Garland, Chief Executive Officer, received $5.8M in total. 50% of Garland's compensation, or $2.9M, was in option awards. Garland also received $200K in bonus, $70K in non-equity incentive plan, $145K in salary, $2.5M in stock awards, as well as $3.1K in other compensation.
William Lis, Chief Executive Officer, received a compensation package of $5.3M, which increased by 8% compared to previous year. 57% of the compensation package, or $3M, was in option awards.
John B. Moriarty, Jr., General Counsel, earned $4.3M in 2018.
Glenn Brame, Executive Vice President, Chief Technical Operations Officer, received $3.2M in 2018.
Ernie Meyer, Chief Human Resources Officer, earned $2.8M in 2018.
Mardi C. Dier, Executive Vice President, Chief Financial and Business Officer, received $2.5M in 2018, which increases by 2% compared to 2017.
John T. Curnutte, Executive Vice President, Research and Development, earned $2.2M in 2018, a 3% increase compared to previous year.

Related executives

Scott Garland

Portola Pharmaceuticals

Chief Executive Officer

Mardi Dier

Portola Pharmaceuticals

Executive Vice President, Chief Financial and Business Officer

John Curnutte

Portola Pharmaceuticals

Executive Vice President, Research and Development

John Moriarty

Portola Pharmaceuticals

General Counsel

Glenn Brame

Portola Pharmaceuticals

Executive Vice President, Chief Technical Operations Officer

Ernie Meyer

Portola Pharmaceuticals

Chief Human Resources Officer

William Lis

Portola Pharmaceuticals

Chief Executive Officer

You may also like

Source: SEC filing on April 19, 2019.